Trial reportNature medicine2024
p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
Abstract readRandomized Controlled TrialClinical Trial, Phase II
In one paragraph
Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- p75 neurotrophin receptor signaling through the RhoA/ROCK pathway contributes to Tau-mediated neurodegeneration.Molecular psychiatry · 2026Article
- Integrated multi-omics analysis identifies potential therapeutic targets for Alzheimer's disease.Neural regeneration research · 2026Article
- Neuronal overexpression of Nrf2 reduces dystrophic neurites in 5XFAD Alzheimer's disease model mice.Alzheimer's research & therapy · 2026Article
- Taming the "death receptor": translating the first-in-class p75Journal of translational medicine · 2026Review
- p75 neurotrophin receptor preserves neuromuscular synapse stability and muscle strength during aging.npj aging · 2026Article
- Caloric restriction attenuates oxidative and inflammatory markers of aging, while compromising germinative epithelium homeostasis in the rat aged testis.Journal of endocrinological investigation · 2026Article
- The Central Role of Neuronal Cell Death in Alzheimer's Disease Pathobiology.Biomedicines · 2026Review
- Alzheimer's disease: from molecular pathways to therapies.Molecular biomedicine · 2026Review
- Locus coeruleus degeneration is associated with cortical tau deposition and cognitive decline in older adults at familial risk of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Palmitoylation of death receptor p75Alzheimer's research & therapy · 2026Article
- Neuronal overexpression of Nrf2 reduces dystrophic neurites in 5XFAD Alzheimer's disease model mice.bioRxiv : the preprint server for biology · 2026Article
- Small molecule modulation of the p75 neurotrophin receptor promotes dendritic spine resilience to pathogenic tau species and reduces their accumulation.Acta neuropathologica communications · 2026Article
- The neuromodulatory fragility hypothesis of Alzheimer's disease pathogenesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Disruption of BDNF signalling in neuropathologies.Biochemical Society transactions · 2026Review
- p75 neurotrophin receptor shapes the dynamics of adult hippocampal neurogenesis in Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Amelioration of Symptomatic Alzheimer's Disease after Selective Impairment of p75The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer's Disease.Molecules (Basel, Switzerland) · 2026Review
- Methodological gaps in cervical LVA for Alzheimer's disease: implications from regulatory intervention.International journal of surgery (London, England) · 2026Article
- Molecular mechanisms of autophagy-lysosomal pathway dysfunction in neurodegenerative diseases and therapeutic strategies for lysosomal repair: a review.Frontiers in neuroscience · 2026Review
- Toward an NGF-based therapy for Rett syndrome.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Hayley R C ShanksSchulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. hayley.r.shanks@gmail.com.ORCID 0000-0003-4502-7170
Kewei ChenBanner Alzheimer's Institute, Phoenix, AZ, USA.ORCID 0000-0001-8497-3069
Eric M ReimanBanner Alzheimer's Institute, Phoenix, AZ, USA.ORCID 0000-0002-0705-3696
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.ORCID 0000-0002-1890-4193
Jeffrey L CummingsChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA.
Stephen M MassaSan Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.ORCID 0000-0003-0474-4886
Frank M LongoPharmatrophiX, Inc., Menlo Park, CA, USA.ORCID 0000-0002-9514-7325
Anne Börjesson-HansonClinical Trials, Department of Aging, Karolinska University Hospital, Stockholm, Sweden.
Manfred WindischNeuroScios, GmbH, St. Radegund, Austria.ORCID 0000-0003-1490-7933
Taylor W SchmitzSchulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. tschmitz@uwo.ca.ORCID 0000-0003-0585-7524
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MTrial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4MResearch Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI ALIREZA ATRI · 2021 to 2026
$24.9MRenewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI Robert J. Fox, Jefferson Kinney · 2015 to 2026
$22.8MA double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.R01AG051596 · NIA · PHARMATROPHIX, INC. · PI WINDISCH, MANFRED · 2016 to 2019
$7.3MNVEDARC Clinical CoreP20AG068053 · NIA · CLEVELAND CLINIC FOUNDATION · PI FOX, ROBERT J. · 2020 to 2022
$3.3MAlzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9MAlzheimer's Disease and Related Dementias Innovation Incubator (InnovaTor)R25AG083721 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI JEFFREY L. CUMMINGS, Xue K Zhong · 2023 to 2026
$1.0MAlzheimer's Association SG-23-1038904 QCAlzheimer's Association ZEN-21-848495Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) 453677NIA NIH HHS P20 AG068053NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG051596NIA NIH HHS R01 AG053798NIA NIH HHS R25 AG083721NIA NIH HHS R35 AG071476NIA NIH HHS U01 AG024904NIGMS NIH HHS P20 GM109025U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) P20GM109025U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) R01AG053798U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) R25 AG083721-01U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) R35AG71476Vetenskapsrådet (Swedish Research Council) 2017-00915Vetenskapsrådet (Swedish Research Council) 2022-00732
Abstract
p75 neurotrophin receptor (p75
Indexed as
Alzheimer DiseasePositron-Emission TomographyAgedAged, 80 and overBiomarkersDouble-Blind MethodFemaleHumansIsoleucineMagnetic Resonance ImagingMaleMiddle AgedMorpholinesNerve Tissue ProteinsReceptor, Nerve Growth FactorReceptors, Nerve Growth FactorBiomarkersIsoleucineLM11A-31MorpholinesNerve Tissue ProteinsNGFR protein, humanReceptor, Nerve Growth FactorReceptors, Nerve Growth Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.